CXCL10 and bladder transitional cell carcinoma: Although the above studies suggest the potential of CXCL10 as a biomarker for immunotherapy in BLCA, overall, there is still a lack of research exploring the relationship between CXCL10 and recent immunotherapies, such as ICIs, in BLCA.